Diagnosis and Management of Mucormycosis: A Rare Fungal Infection in COVID-19 Patients | Chapter 10 | New Advances in Medicine and Medical Science Vol. 6

 This member presents an experience of 90 victims of invasive fungal sinusitis over the past 3 months victims being presenting in addition to COVID-19 or as a post covid19 sequel. Since the emergence of the COVID-19 universal, it has been doubtful that mucormycosis might cause signifcant morbidity to contaminated patients. There are diversified possible contributing determinants for the development of mucormycosis with patients with COVID-19 and these contain diabetes mellitus, obesity, use of corticosteroid, and the incident of cytokine storms.We have studied 90 patients of obtrusive fungal sinusitis at tertiary care centers over a ending of 3 months from March 2021 to June 2021 prospectively.The widespread use of corticosteroids/monoclonal antibodies/general antibiotics as part of the situation against COVID-19 may bring about the development/exacerbation of pre-existent fungal diseases. A total of 67 men and 23 females of age group 41 to 70 age were presented as cases of obtrusive fungal sinusitis with suspicion of Mucormycosis. In our study 48 at a distance 90 (53%) patients need surgical cure. One of these sufferers was cured by Caldwell Luc surgery. Most of the staying patients either conducted with functional endoscopic cavity surgery (FESS) unique (70%) or combined with Caldwell Luc (12.5%) or maxillectomy (14.5%).With the COVID-19 universal, invasive fungal sinusitis, containing the formerly exceptional illness mucormycosis, has become much more universal. Invasive fungal illnesses act the rise, and factors include invulnerable dysregulation brought on by COVID-19, diabetes mellitus, and extensive use of corticosteroids and antibiotics are all to blame.  Early disease, surgical intervention and antifungal situation help to reduce mortality and depression. A high degree of dispassionate suspicion is needed to determine Mucormycosis and timely hostile management is necessary to help outcome in Mucormycosis.

Author(s) Details:

Anuja A. Samale,
Department of Microbiology, GMC, Aurangabad, Maharashtra, India.

Vimal S. Rathod,
Department of Microbiology, Dr. SCGMC, Nanded, Maharashtra, India.

Sanjaykumar R. More,
Department of Microbiology, Dr. SCGMC, Nanded, Maharashtra, India.

Atish B. Gujrathi,
Department of Ear Nose and Throat (ENT), Dr. SCGMC, Nanded, Maharashtra, India.

Please see the link here: https://stm.bookpi.org/NAMMS-V6/article/view/10991